Psyence Biomedical Says It Remains Confident That PsyLabs Is On Track To Produce GMP Certified, Nature-derived Psychedelic APIs

Following the successful export of its psilocybin extract to its CDMO in the UK, PsyLabs has now entered phase two of its development process.

The CDMO has commenced work on upscaling the purification process to validate its commercial viability, ensuring that the extraction methodology developed by PsyLabs can be efficiently scaled for larger production volumes.

This critical phase will confirm that the methods used to achieve PsyLabs' high-purity psilocybin can be replicated on a commercial scale, setting the foundation for E.U. GMP certification.